Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating ...

Canaccord raised the firm’s price target on Travere Therapeutics (TVTX) to $45 from $22 and keeps a Buy rating on the shares. The firm noted ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Exelixis Inc (EXEL) reports robust financial performance and outlines ambitious goals for its oncology portfolio amid market ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target on Travere Therapeutics (NASDAQ:TVTX) to $32.00, up from the previous $27.00, while retaining a Sector Outperform rating for the ...

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...